Mo Qatanani Sells 13,112 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Mo Qatanani sold 13,112 shares of the company’s stock in a transaction that occurred on Wednesday, January 14th. The shares were sold at an average price of $45.20, for a total transaction of $592,662.40. Following the completion of the transaction, the insider owned 108,964 shares in the company, valued at approximately $4,925,172.80. This represents a 10.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Mo Qatanani also recently made the following trade(s):

• On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The shares were sold at an average price of $45.21, for a total transaction of $6,169,447.02.

Scholar Rock Trading Down 3.4%

NASDAQ SRRK opened at $44.97 on Friday. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a 1-year low of $22.71 and a 1-year high of $48.28. The firm’s fifty day simple moving average is $42.34 and its 200-day simple moving average is $36.96. The company has a market capitalization of $4.59 billion, a PE ratio of -14.28 and a beta of 0.63.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same quarter in the previous year, the firm posted ($0.66) earnings per share. As a group, sell-side analysts anticipate that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current fiscal year.

Key Headlines Impacting Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Several sell-side firms have maintained or raised constructive ratings and price targets (consensus ~ $50+), which supports longer-term interest in the name.
• Positive Sentiment: Large institutional positions and recent additions (e.g., Norges Bank, other funds) mean professional investors are committed to SRRK, which can support the share base despite short-term volatility.
• Neutral Sentiment: Company fundamentals: Scholar Rock is a clinical-stage biotech focused on growth-factor biology (lead program SRK‑015 for SMA). It has strong liquidity metrics (high current/quick ratios), which reduces near‑term financing risk.
• Negative Sentiment: CEO David Hallal sold 57,450 shares at ~$42.70 on Jan 13 — a large single insider sale that can be interpreted negatively by the market. CEO Form 4
• Negative Sentiment: COO Keith Woods sold 16,746 shares (~$42.70) on Jan 13. Aggregate exec selling increases perceived near-term supply pressure. COO Form 4
• Negative Sentiment: CFO Vikas Sinha sold 16,755 shares (~$42.70) on Jan 13, and other insiders including Akshay Vaishnaw and Mo Qatanani also reduced positions in mid‑January — the cluster of senior-level sales is likely the main driver of today’s weakness. CFO Form 4 Vaishnaw Form 4 Qatanani Form 4
• Negative Sentiment: Prior quarterly EPS (Nov 14) missed estimates modestly, which keeps upside tied to clinical progress and future data rather than near-term earnings.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research report on Wednesday, October 8th. BMO Capital Markets reiterated an “outperform” rating and issued a $50.00 target price on shares of Scholar Rock in a report on Friday, November 14th. Barclays upped their price target on shares of Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Piper Sandler dropped their price objective on Scholar Rock from $52.00 to $51.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 24th. Finally, HC Wainwright cut their price objective on Scholar Rock from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, September 23rd. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $50.14.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SRRK. Vanguard Group Inc. lifted its stake in shares of Scholar Rock by 1.1% in the third quarter. Vanguard Group Inc. now owns 4,914,927 shares of the company’s stock valued at $183,032,000 after buying an additional 53,333 shares during the period. Wellington Management Group LLP raised its holdings in Scholar Rock by 124.5% in the 3rd quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock valued at $169,289,000 after acquiring an additional 2,521,022 shares in the last quarter. Bellevue Group AG lifted its position in shares of Scholar Rock by 10.1% in the 3rd quarter. Bellevue Group AG now owns 3,244,537 shares of the company’s stock worth $120,827,000 after acquiring an additional 297,242 shares during the period. Eventide Asset Management LLC grew its holdings in shares of Scholar Rock by 9.5% during the 2nd quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company’s stock worth $103,192,000 after purchasing an additional 251,638 shares in the last quarter. Finally, Holocene Advisors LP bought a new stake in shares of Scholar Rock during the third quarter valued at approximately $91,670,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).